| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d39b312055964c01a67f88aedcdf5d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7caba5203a170a068ada5a4e452a51f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2b5d8555884c2c473d52c1c80375505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 |
| filingDate |
2019-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd2509da8dd45f8c066915cd720dd53a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38f776e32169f2c5b639238c1ea9d163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab51c29d59111ccfb85be9831d257322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ca6ed317689600c607d4ecd08457ead |
| publicationDate |
2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019152982-A1 |
| titleOfInvention |
Heterobicyclic compounds as ep4 antagonists |
| abstract |
The present invention relates to novel EP4 receptor antagonist compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, which can be useful for treating cancer or inflammatory diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022102731-A1 |
| priorityDate |
2018-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |